Neurotech Newsletter #22
January 30, 2026
Executive Summary
Welcome to the 22nd edition of the Carter Sciences Neurotech Newsletter!
Neurotech kicks off 2026 with explosive momentum: $4.8 billion in 2025 funding fueling BCI IPOs like BrainCo's Hong Kong debut and strategic acquisitions in neuromodulation, FDA breakthroughs including PMA approval for at-home depression therapy and clearances for innovative devices, clinical frontiers from thought-controlled spinal stimulation and long COVID light therapy to safer DBS profiles, a flurry of C-suite hires and MS advisors at firms like CIONIC, and game-changing partnerships such as Precision Neuroscience with Medtronic—signaling accelerated commercialization, non-invasive innovation, and ecosystem maturation poised to transform neurology.
Check out the highlights below and as always send through any recommendations or feedback to chay@cartersciences.com
Funding News
2026 Consumer Health Trends Report Preview
NaturalX Report | January 30, 2026
The 2026 Consumer Health Trends Report highlights how consumer health is reshaping healthcare as systems face overload from chronic diseases, with consumers stepping in via wearables for mainstream health tracking and actively seeking health information weekly, positioning consumers as CEOs of their own health.
BrainCo heads for Hong Kong IPO as China’s brain-tech champions go public
PE Insights | January 30, 2026
BrainCo, a Chinese brain-computer interface startup, has confidentially filed for a Hong Kong IPO with China International Capital Corp and UBS, potentially raising several hundred million dollars and marking a public debut for one of China's top next-gen tech firms.
Resonetics to Acquire Resolution Medical, Expanding Neuromodulation Capabilities
PR Newswire | January 27, 2026
Resonetics has signed an agreement to acquire Resolution Medical, a provider of design and manufacturing for complex medical devices headquartered in Fridley, MN, with operations in the Netherlands and owned by Arcline Investment Management, to expand in neuromodulation and structural heart markets.
The New Gold Rush in Brain Science
BioSpace | January 22, 2026
Fueled by biomarkers, brain mapping, and AI advances, investment in neuro and CNS innovation remains strong despite setbacks, as venture capitalists at JPM26 express keen interest in new therapies and neurotech.
Juniper Biomedical Wins Phase 3 NIH SPARC Neuromod Prize And Adds Frank Fischer to Board
Pulse 2 | January 20, 2026
Juniper Biomedical won Phase 3 of the NIH SPARC Neuromod Prize, securing $1.6 million to advance its therapy for mixed urinary incontinence, adding to prior Phase 1 and 2 wins for a total of $2.9 million.
2025 Neurotech Funding Snapshot
Neurotech Futures | January 12, 2026
Neurotech saw $4.8 billion in private investments across 140 deals in 2025, providing insights into commercial markets through analysis of capital flows as outlined in Neurotech Futures’ snapshot.
Boston Scientific to buy incontinence device maker Valencia
MedTech Dive | January 12, 2026
Boston Scientific agreed to acquire Valencia Technologies, developer of the FDA-approved eCoin tibial nerve stimulator for urinary urge incontinence, to expand its pelvic health portfolio into a high-growth neuromodulation area.
Industry Analysis
These funding developments, including BrainCo's potential Hong Kong IPO, acquisitions by Resonetics and Boston Scientific, a $1.6 million NIH prize to Juniper Biomedical, and $4.8 billion in 2025 neurotech investments, signal robust capital inflow and strategic consolidation, likely accelerating innovation in brain-computer interfaces and neuromodulation while enhancing market access and scalability for neurotech firms amid growing investor interest in CNS therapies.
Trend Conclusion
Trends point to surging M&A activity in neuromodulation, public market debuts for BCI leaders like BrainCo, sustained private funding at record levels, and government-backed prizes fueling clinical advancement, alongside consumer-driven health tracking via wearables, collectively driving neurotechnology towards broader commercialization and integration into mainstream healthcare in 2026.
Regulatory & Reimbursement News
Sonomotion Announces FDA Clearance for Break Wave Lithotripsy Device
PR Newswire | 2026-01-21
SonoMotion received FDA 510(k) clearance for its Break Wave lithotripsy device, which employs low-pressure focused ultrasound to fragment kidney stones via standing stress waves under real-time imaging guidance, marking a non-invasive advancement for urological treatments.
ReVision Implant Awarded FDA Breakthrough Device Designation
LinkedIn | 2026-01-14
The ReVision Implant earned FDA Breakthrough Device Designation, accelerating development and review for its potential to address life-threatening or debilitating conditions through prioritized FDA interactions.
Neurolief Receives FDA PMA Approval for Proliv Rx Therapy
PR Newswire | 2026-01-12
Neurolief's Proliv Rx gained FDA PMA approval as the first at-home, physician-directed brain neuromodulation therapy for adults with major depressive disorder inadequately managed by antidepressants, expanding adjunctive treatment options.
Regulatory Impact Analysis
These FDA actions underscore accelerated pathways for innovative neurodevices, with PMA approval for at-home neuromodulation and Breakthrough Designation for implants potentially lowering barriers to market entry, enabling neurotechnology firms to address unmet needs in neuropsychiatric and debilitating conditions faster while enhancing patient access to non-invasive therapies.
Regulatory Trend Conclusion
Early 2026 developments signal a trend toward FDA prioritization of neuromodulation innovations, from 510(k) clearances for ultrasound-based tech to expedited designations and full PMA approvals for home-use brain stimulation, reflecting growing support for outpatient neurotherapies amid rising mental health demands.
Clinical News
Transcranial focused ultrasound for identifying the neural substrate of conscious perception
ScienceDirect | 2026-01-30
Transcranial focused ultrasound emerges as a breakthrough non-invasive brain stimulation technique offering millimeter-scale resolution to probe specific brain structures' roles in conscious perception among healthy humans, with a proposed roadmap to test competing theories of consciousness.
Cervical VNS Elicits Stronger Responses Than Auricular VNS
PubMed | 2026-01-30
A study comparing noninvasive vagus nerve stimulation reveals cervical VNS produces stronger parasympathetic responses and alpha EEG activity linked to relaxation than auricular VNS, attributed to five-to-six times more Aβ-fibers and bidirectional fiber composition in the cervical branch.
Pilot Trial Shows Safety of Accelerated tAN for Depression and Anxiety
LinkedIn | 2026-01-27
The open-label iWAVE pilot trial in Neuromodulation demonstrates safety and feasibility of accelerated transcutaneous auricular neurostimulation for inpatient comorbid depression and anxiety, with both dosing schedules well-tolerated and no serious adverse events.
ONWARD Medical Completes Two Additional BCI Implants
Yahoo Finance | 2026-01-22
ONWARD Medical advances its investigational ARC-BCI therapy by completing two additional brain-computer interface implants paired with spinal cord stimulation, targeting thought-driven movement restoration in spinal cord injury patients as the first purpose-designed platform of its kind.
New Clinical Study Shows Music Can Be “Dosed” Like Medicine
PLOS Mental Health | 2026-01-21
A randomized trial in PLOS Mental Health finds 24 minutes of music with auditory beat stimulation significantly reduces anxiety, positioning music as a precision, evidence-based dosable therapy.
Hyperfine Announces NEURO PMR Study Results
Hyperfine | 2026-01-20
NEURO PMR study results, presented at the American Society of Neuroimaging, validate Hyperfine's portable Swoop MRI system's high diagnostic value and superior patient experience in outpatient neurology clinics.
Epiminder’s US Trial Start Raises Stakes in Drug-Resistant Epilepsy Care
Middle News | 2026-01-19
Epiminder achieves first US implant of its Minder System at University of Pennsylvania, launching the pivotal DETECT randomized trial comparing continuous EEG monitoring to standard care for drug-resistant epilepsy across five centers and up to 25 sites with 210 patients.
Wiley Online Library | 2026-01-19
A retrospective NSQIP cohort study of 2.8 million elective surgeries positions deep brain stimulation risks as comparable to common procedures like cholecystectomy, potentially alleviating underutilization barriers for movement disorders, epilepsy, and psychiatric treatments.
Magnetic NeuroRing: Portable BCI for Post-Stroke TMS Rehabilitation
Nature | 2026-01-16
The Magnetic NeuroRing portable brain-computer interface integrates real-time EEG with closed-loop continuous theta burst transcranial magnetic stimulation to promote neural reorganization and rehabilitate persistent upper limb motor dysfunction after stroke.
GlobeNewswire | 2026-01-14
A randomized double-blind sham-controlled trial shows non-invasive home-based light therapy yields measurable cognitive improvements in adults under 45 with long COVID brain fog, addressing a condition impairing workforce participation and mental health.
PathMaker Neurosystems Completes ALS Early-Feasibility Study
GlobeNewswire | 2026-01-12
PathMaker Neurosystems completes its early-feasibility study of the non-invasive MyoRegulator device, evaluating its potential as a treatment for amyotrophic lateral sclerosis patients.
Nia Therapeutics Publishes In Vivo SNS Validation Data
Medical Device Network | 2026-01-05
Nia Therapeutics publishes first in vivo validation of its wireless implantable Smart Neurostimulation System brain-computer interface, enabling 60-channel neural recordings across four brain regions for closed-loop applications in memory disorders.
Longitudinal multitask wireless ECoG data from implanted primates
Nature | 2025-12-11
A unique dataset provides chronic wireless electrocorticography recordings from two implanted Japanese macaques over hundreds of days, with bilateral subdural arrays on sensorimotor cortices during multitask activities.
Clinical Impact Analysis
These advancements in non-invasive neuromodulation, portable BCIs, imaging, and safety validations across epilepsy, depression, ALS, stroke, and long COVID signal accelerated clinical translation in neurotechnology, reframing procedural risks, enhancing home-based therapies, and expanding access to precise diagnostics and personalized interventions for improved patient mobility, cognition, and quality of life.
Research Trend Conclusion
Prominent trends include proliferation of non-invasive stimulation (tFUS, VNS, light/music therapies), closed-loop implantable BCIs for chronic recording and modulation, portable diagnostics, and early-phase trials prioritizing safety/feasibility in diverse neurological conditions, driving towards multimodal, patient-centric neurotech integration.
Commercial Collaborations and Launches
Evolution isn’t optional. Today, Nexstem becomes Anthriq.
Anthriq | 2026-01-30
Nexstem has rebranded to Anthriq to reflect its evolved focus on building intelligence around human biosignals, expanding from initial thought-controlled prosthetics into a broader foundational platform with the same core team and direction.
Sleep WISP™ - New Patent Allowed for Glymphatic Clearance Monitoring and Enhancement
Neurosom | 2026-01-30
Neurosom has secured patent allowance for its Sleep WISP product, protecting innovations in monitoring and enhancing glymphatic clearance during sleep to potentially prevent neurodegenerative diseases like Alzheimer’s and Parkinson’s.
Reccy Neuro Launches Specialized Neurotech Job Platform
LinkedIn | 2026-01-26
Reccy Neuro launched a dedicated job platform for neurotechnology roles, curating opportunities in brain-computer interfaces and related fields to connect specialists with startups and enterprises more efficiently.
NeuraLight and Teitur Trophics Announce Collaboration for TT-P34 Trial
BioSpace | 2026-01-22
NeuraLight and Teitur Trophics formed a collaboration to integrate NeuraLight's precision biomarker platform into the TT-P34 clinical trial for Parkinson’s disease, enhancing trial outcomes with advanced brain function measures.
Dave Mugan Launches NeuroStim Solutions as Founder
LinkedIn | 2026-01-22
Dave Mugan launched NeuroStim Solutions as founder and principal advisor, focusing on neuromodulation advisory and clinical strategy to support neurotech commercialization.
Atlas Joins NBA Launchpad for Mental Performance Wearable Pilot
LinkedIn | 2026-01-21
Atlas was selected for the NBA Launchpad program to pilot its mental performance wearable, providing real-time mental state insights to support peak performance in basketball and business applications.
Pupil Labs and NIL Technology Announce Pilot Product Partnership
Pupil Labs | 2026-01-19
Pupil Labs partnered with NIL Technology on a pilot product to integrate NILT’s metaEye ultra-compact optics into Pupil Labs’ NeonNet AI eye-tracking pipeline for next-generation wearable eye tracking.
Merge Labs | 2026-01-15
Merge Labs launched as a research lab developing high-bandwidth brain-computer interfaces integrated with AI to bridge biological and artificial intelligence, enhancing human ability and experience.
Precision Neuroscience and Medtronic Partner on BCI Integration
GlobeNewswire | 2026-01-12
Precision Neuroscience partnered with Medtronic to co-develop an integrated neurosurgical solution combining Precision’s Layer 7 cortical BCI with Medtronic’s StealthStation navigation system.
Market Impact Analysis
These commercial activities, spanning rebrands, patent protections, platform launches, and strategic partnerships with industry giants like Medtronic and the NBA, are poised to heighten competition in neurotech by accelerating BCI integration, clinical validations, and wearable adoption, while bolstering business strategies through pilots and IP fortification to drive faster market entry and industry-wide growth in neurodegeneration and performance monitoring sectors.
Commercial Trend Conclusion
A clear trend emerges toward ecosystem-building collaborations, including pilot partnerships for hardware integration and clinical biomarkers, alongside new entity launches focused on BCI, neuromodulation, and talent platforms, signaling a maturing neurotech landscape prioritizing high-bandwidth interfaces, preventive therapies, and scalable go-to-market via established networks.
Leadership Appointments
Jonathan B. Joins Thynk Inc as VP of Sales
LinkedIn | 2026-01-30
Jonathan B. has joined Thynk Inc. as VP of Sales, bringing experience from IEP&Me where he built market momentum and positioned the company for growth, now set to scale Thynk's mission addressing meaningful challenges with a dynamic team.
CIONIC Adds Dr. Myla Goldman to Scientific Advisory Board
LinkedIn | 2026-01-28
CIONIC appoints Dr. Myla Goldman, chief of neuroimmunology at Virginia Commonwealth University, to its Scientific Advisory Board, leveraging her expertise in multiple sclerosis outcomes and comorbidities to advance the Neural Sleeve for MS patients.
Subsense Appoints Levin and Halas to Advisory Boards
LinkedIn | 2026-01-27
Subsense Inc. appoints John-Clark Levin, Research Lead at Kurzweil Technologies with AI, policy, and life sciences expertise from Harvard, Cambridge, and advisory roles, to its Product Advisory Board, enhancing strategic guidance alongside another expert on advisory boards.
Sevaro Appoints Vineet Agrawal as Head of Growth
LinkedIn | 2026-01-26
Sevaro names Vineet Agrawal Head of Growth, drawing on 11 years at Penumbra leading neurovascular stroke expansion, commercial teams, and market access to drive platform adoption and partnerships in neurology.
Motif Neurotech Appoints Paula Dassbach as Director of Program Management
LinkedIn | 2026-01-22
Motif Neurotech appoints Paula Dassbach, PhD, as Director of Program Management, with her background in organizational development, change management, and neurotechnology roles at Medtronic and Synchron to guide complex initiatives.
Cionic Appoints Dr. Barry Singer to Scientific Advisory Board
LinkedIn | 2026-01-20
Cionic appoints Dr. Barry Singer, MD, founder and director of the MS Center for Innovations at Missouri Baptist Medical Center and host of the MS Living Well podcast, to its Scientific Advisory Board.
Dean Karantonis Appointed CTO at Saluda Medical
LinkedIn | 2026-01-20
Dean Karantonis joins Saluda Medical as Chief Technology Officer, tasked with leading technology initiatives in the neurotechnology sector.
Professor John Harrison Joins Xylo Bio as Clinical Cognition Advisor
LinkedIn | 2026-01-16
Xylo Bio appoints Professor John Harrison as Clinical Cognition Advisor, a leading expert in cognition from prior roles as CSO at Scottish Brain Sciences, Neurotrack, and Cogstate.
Firefly Neuroscience Appoints Doug Morgan as Head of Product and Engineering
LinkedIn | 2026-01-15
Firefly Neuroscience appoints Doug Morgan as Head of Product and Engineering, with over 15 years scaling engineering, product, and machine learning teams at startups and enterprises, holding degrees from Georgia Tech.
Subsense Appoints Chief of Staff, R&D Manager, and Product Manager
LinkedIn | 2026-01-14
Subsense Inc. strengthens leadership with Andrew Ostarello as Chief of Staff from Only Choices, Vandana V. as R&D Project Manager from NASA Ames, and a Product Manager, enhancing executive coordination and R&D execution.
Brainreader Appoints Cyrus A. Raji as Chief Medical Officer
Brainreader | 2026-01-14
Brainreader appoints Cyrus A. Raji, MD, PhD, tenured Associate Professor of Radiology and Neurology at Washington University in St. Louis, as consulting Chief Medical Officer to lead advanced brain volumetric analysis efforts.
CIONIC Appoints Brooke Harding as Chief Commercial Officer
LinkedIn | 2026-01-13
CIONIC appoints Brooke Harding as Chief Commercial Officer, former CEO of Aria Health, to drive commercialization of integrated medical devices with a focus on payer coverage and transformative outcomes.
Jeff Huynh Joins Epitel as Director of Marketing
LinkedIn | 2026-01-13
Jeff Huynh joins Epitel as Director of Marketing, applying MedTech growth and commercial strategy experience to advance brain monitoring solutions.
PainTEQ Announces Appointment of Lalit Venkatesan, PhD as Senior Vice President of Clinical Research
PR Newswire | 2026-01-13
PainTEQ appoints Lalit Venkatesan, PhD, as Senior Vice President of Clinical Research to oversee evidence generation, scientific communications, and clinical development for minimally invasive SI joint solutions.
Kris Krustangel Joins Noctrix Health as SVP of Sales
LinkedIn | 2026-01-12
Kris Krustangel joins Noctrix Health as SVP of Sales and Commercial Operations, bolstering commercial leadership for innovative neurotechnology solutions.
Leadership Impact Analysis
These appointments signal a robust push in neurotechnology towards clinical expertise and commercial scaling, with firms like CIONIC enhancing MS-focused advisory boards and others adding growth, sales, and R&D leaders to accelerate product development, market access, and evidence generation amid rising demand for neuromodulation, brain monitoring, and mobility solutions.
Executive Trend Conclusion
Trends reveal heavy emphasis on neurology specialists for advisory roles, C-suite commercial hires, and operational experts in program management and engineering, underscoring the neurotech sector's maturation from innovation to commercialization and interdisciplinary integration for neurological disorders.
Closing Thoughts
Key Strategic Insights
Robust $4.8 billion in 2025 neurotech funding, coupled with high-profile acquisitions like Boston Scientific's Valencia buyout and BrainCo's Hong Kong IPO filing, underscores surging investor confidence in neuromodulation and BCI scalability, amplified by FDA fast-tracks such as Neurolief's at-home Proliv Rx PMA and Breakthrough Designation for ReVision Implant, while clinical breakthroughs in non-invasive tFUS, closed-loop BCIs from ONWARD and Nia, and safety reframing for DBS signal a pivot from R&D to deployable therapies addressing depression, epilepsy, ALS, stroke, and long COVID brain fog.
Cross-Functional Analysis
Funding fuels clinical acceleration—evident in NIH SPARC prizes for Juniper Biomedical and Epiminder's epilepsy trial—while regulatory nods enable commercial momentum through partnerships like Precision Neuroscience-Medtronic BCI integration and NeuraLight-Teitur Trophics biomarkers, with leadership hires at CIONIC, Saluda Medical, and Firefly Neuroscience stacking sales, growth, and clinical expertise to bridge neuromodulation innovations (e.g., cervical VNS superiority, portable Swoop MRI) into consumer wearables like Atlas's NBA pilot and preventive platforms like Neurosom's Sleep WISP, forging a cohesive ecosystem from lab to market.
Future Outlook & Recommendations
Expect intensified M&A in neuromodulation and BCI, global IPOs from China-led brain-tech, and proliferation of home-based, non-invasive therapies amid mental health and neurodegeneration demands; executives should prioritize cross-sector alliances (e.g., sports-performance pilots scaling to enterprise), talent acquisition in commercial ops and neuro specialists, IP fortification for glymphatic/AI biomarkers, and regulatory prep for accelerated pathways to capture consumer-driven health tracking trends projected in 2026 reports.
Final Word
Neurotech's convergence of capital, clearance, and capability positions 2026 as the year of mainstream integration—seize the momentum or risk obsolescence.
© 2026 Carter Sciences. All rights reserved.
This newsletter is compiled for professionals in the Neurotechnology industry.
